PURPOSE: The aim of this study was to determine the value of CA 19-9 in therapy monitoring and follow-up of locally advanced pancreatic cancer treated by radiochemotherapy. MATERIALS AND METHODS: Ninety-five patients with locally advanced irresectable adenocarcinoma of the pancreas were treated with hyperfractionated accelerated radiotherapy, with 44.8 Gy and 5-fluorouracil and folinic acid, January 1994 between and June 2001. CA 19-9 was measured before therapy, each week under therapy and every 4 weeks in the follow-up. RESULTS: Median CA 19-9 before treatment was 420 U/ml. Patients with a level below the median had significantly better prognosis and a better treatment response than those above the median. In the follow-up CA 19-9 had a sensitivity of 100% in detection of recurrent disease with a specificity of 88. CONCLUSION: CA 19-9 has a high prognostic value and may serve as an in vivo marker for treatment sensitivity. For detection of recurrent disease it shows a high sensitivity and specificity.
PURPOSE: The aim of this study was to determine the value of CA 19-9 in therapy monitoring and follow-up of locally advanced pancreatic cancer treated by radiochemotherapy. MATERIALS AND METHODS: Ninety-five patients with locally advanced irresectable adenocarcinoma of the pancreas were treated with hyperfractionated accelerated radiotherapy, with 44.8 Gy and 5-fluorouracil and folinic acid, January 1994 between and June 2001. CA 19-9 was measured before therapy, each week under therapy and every 4 weeks in the follow-up. RESULTS: Median CA 19-9 before treatment was 420 U/ml. Patients with a level below the median had significantly better prognosis and a better treatment response than those above the median. In the follow-up CA 19-9 had a sensitivity of 100% in detection of recurrent disease with a specificity of 88. CONCLUSION: CA 19-9 has a high prognostic value and may serve as an in vivo marker for treatment sensitivity. For detection of recurrent disease it shows a high sensitivity and specificity.
Authors: Cristina R Ferrone; Dianne M Finkelstein; Sarah P Thayer; Alona Muzikansky; Carlos Fernandez-delCastillo; Andrew L Warshaw Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: H S Wasan; G M Springett; C Chodkiewicz; R Wong; J Maurel; C Barone; B Rosbrook; A D Ricart; S Kim; J-P Spano Journal: Br J Cancer Date: 2009-09-01 Impact factor: 7.640
Authors: David B Shultz; Jonathan Pai; Wayland Chiu; Kendall Ng; Madeline G Hellendag; Gregory Heestand; Daniel T Chang; Dongsheng Tu; Malcolm J Moore; Wendy R Parulekar; Albert C Koong Journal: PLoS One Date: 2016-01-25 Impact factor: 3.240